ADAR mediated RNA editing for treatment of collagen VI related muscular dystrophy

Awardee: Russell Butterfield

Institution: University of Utah

Grant Amount: $70,133.00

Funding Period: February 1, 2024 - January 31, 2025


Summary:

The collagen VI related muscular dystrophies (COL6-RD) are inherited disorders of muscle characterized by progressive weakness and a combination of distal joint laxity and proximal joint contractures. Missense mutations substitute the glycine residues in the conserved Gly-x-y repeat of the triple helical (TH) domain are the most common mutation in COL6-RD patients. This mutation allows incorporation of abnormal chains into secreted tetramers resulting in a dominant negative effect. Currently, there are no treatment for these disorders and the dominant negative mutations pose significant challenges for developing novel treatments since simple gene-replacement will not be effective to counter the dominant-negative mechanism. In this study, we propose to apply an in-situ RNA editing strategy by recruiting adenosine deaminase acting on RNA (ADAR) with guide RNA to simultaneously correct multiple G-to-A dominant negative mutations in COL6-RD patient-derived fibroblasts. We hypothesize this strategy will significantly decrease the mutant alleles’ presence at mRNA level and result in decreased intracellular retention and increased deposition of collagen VI matrix.

Previous
Previous

Developing peptide-conjugated antisense oligonucleotide therapy for COL6-related congenital muscular dystrophy

Next
Next

pH-dependent mechanisms of disease caused by TBC1D24 mutations